YU22499A - Stabilizovane farmaceutske smeše na bazi hinupristina i dalfopristina i njihovo dobijanje - Google Patents

Stabilizovane farmaceutske smeše na bazi hinupristina i dalfopristina i njihovo dobijanje

Info

Publication number
YU22499A
YU22499A YU22499A YU22499A YU22499A YU 22499 A YU22499 A YU 22499A YU 22499 A YU22499 A YU 22499A YU 22499 A YU22499 A YU 22499A YU 22499 A YU22499 A YU 22499A
Authority
YU
Yugoslavia
Prior art keywords
dalfopristine
base
quinupristine
preparation
pharmaceutical compositions
Prior art date
Application number
YU22499A
Other languages
English (en)
Inventor
Jean-Paul Bounine
Guillaume Conrata
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of YU22499A publication Critical patent/YU22499A/sh
Publication of RS49608B publication Critical patent/RS49608B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Stabilizovana farmaceutska smeša, na bazi asocijacije hinupristin/dalfopristin koja obuhvata najmanje stehiometrijsku količinu metansulfonske ili hlorovodonične kiseline i njena vrednost pH je u intervalu od 3,5 do 5.[The invention concerns a stabilised pharmaceutical composition, with a combined quinopristine/dalfopristine base, containing at least a stoichiometric amount of methanesulphonic acid or hydrochloric acid and is characterised in that its pH is included in the {3.5; 5} interval.
YUP-224/99A 1996-11-19 1997-11-14 Stabilizovane farmaceutske smeše na bazi hinupristina i dalfopristina i njihovo dobivanje RS49608B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9614062A FR2755857B1 (fr) 1996-11-19 1996-11-19 Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation

Publications (2)

Publication Number Publication Date
YU22499A true YU22499A (sh) 2002-03-18
RS49608B RS49608B (sr) 2007-06-04

Family

ID=9497744

Country Status (45)

Country Link
US (1) US5994338A (sh)
EP (1) EP0949923B1 (sh)
JP (1) JP4278115B2 (sh)
KR (1) KR100530836B1 (sh)
CN (1) CN1146417C (sh)
AP (1) AP998A (sh)
AR (1) AR008695A1 (sh)
AT (1) ATE223217T1 (sh)
AU (1) AU740291B2 (sh)
BG (1) BG63621B1 (sh)
BR (1) BR9713087A (sh)
CA (1) CA2271095C (sh)
CO (1) CO4910113A1 (sh)
CZ (1) CZ299913B6 (sh)
DE (1) DE69715247T2 (sh)
DK (1) DK0949923T3 (sh)
DZ (1) DZ2349A1 (sh)
EA (1) EA002025B1 (sh)
EE (1) EE03668B1 (sh)
ES (1) ES2179375T3 (sh)
FR (1) FR2755857B1 (sh)
HK (1) HK1022832A1 (sh)
HR (1) HRP970615B1 (sh)
HU (1) HUP9904327A3 (sh)
IL (2) IL129607A0 (sh)
IN (1) IN187038B (sh)
JO (1) JO1992B1 (sh)
MA (1) MA26448A1 (sh)
MY (1) MY123805A (sh)
NO (1) NO992399D0 (sh)
NZ (1) NZ334949A (sh)
OA (1) OA11047A (sh)
PE (1) PE13999A1 (sh)
PL (1) PL190164B1 (sh)
PT (1) PT949923E (sh)
RS (1) RS49608B (sh)
SA (1) SA97180645B1 (sh)
SK (1) SK284311B6 (sh)
TN (1) TNSN97184A1 (sh)
TR (1) TR199901096T2 (sh)
TW (1) TW474816B (sh)
UA (1) UA59376C2 (sh)
UY (1) UY24780A1 (sh)
WO (1) WO1998022107A1 (sh)
ZA (1) ZA9710435B (sh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
HU230656B1 (hu) 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
AU776782C (en) * 1999-03-03 2005-04-07 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
US6119269A (en) * 1999-09-23 2000-09-19 Imler; Jack Fishing vest with removable storage container system
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
FR2812549B1 (fr) * 2000-08-03 2003-03-21 Aventis Pharma Sa Associations dalfopristine/quinupristine avec le cefpirome
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549065B1 (fr) * 1983-07-13 1985-10-25 Rhone Poulenc Sante Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2576022B1 (fr) * 1985-01-11 1987-09-11 Rhone Poulenc Sante Nouveaux derives de la pristinamycine ii b, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2599036B1 (fr) * 1986-05-22 1988-09-09 Rhone Poulenc Sante Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
ES2179375T3 (es) 2003-01-16
FR2755857B1 (fr) 1998-12-24
EE9900127A (et) 1999-12-15
CZ299913B6 (cs) 2008-12-29
EA199900479A1 (ru) 2000-02-28
HUP9904327A2 (hu) 2000-06-28
PL190164B1 (pl) 2005-11-30
EE03668B1 (et) 2002-04-15
KR100530836B1 (ko) 2005-11-23
PT949923E (pt) 2003-01-31
SA97180645B1 (ar) 2005-12-12
UA59376C2 (uk) 2003-09-15
HK1022832A1 (en) 2000-08-25
BG103412A (en) 2000-06-30
MA26448A1 (fr) 2004-12-20
HUP9904327A3 (en) 2002-03-28
HRP970615A2 (en) 1998-08-31
EA002025B1 (ru) 2001-12-24
UY24780A1 (es) 2001-08-27
CA2271095A1 (fr) 1998-05-28
IN187038B (sh) 2001-12-29
AP998A (en) 2001-08-09
MY123805A (en) 2006-06-30
CN1233959A (zh) 1999-11-03
CN1146417C (zh) 2004-04-21
AU740291B2 (en) 2001-11-01
PE13999A1 (es) 1999-05-05
DK0949923T3 (da) 2002-12-23
BG63621B1 (bg) 2002-07-31
US5994338A (en) 1999-11-30
SK284311B6 (sk) 2005-01-03
WO1998022107A1 (fr) 1998-05-28
IL129607A (en) 2006-08-20
DE69715247T2 (de) 2003-04-30
TW474816B (en) 2002-02-01
AR008695A1 (es) 2000-02-09
NO992399L (no) 1999-05-19
EP0949923B1 (fr) 2002-09-04
DZ2349A1 (fr) 2002-12-28
JO1992B1 (en) 1999-05-15
HRP970615B1 (en) 2002-12-31
JP2001504475A (ja) 2001-04-03
CO4910113A1 (es) 2000-04-24
FR2755857A1 (fr) 1998-05-22
JP4278115B2 (ja) 2009-06-10
BR9713087A (pt) 2000-03-28
RS49608B (sr) 2007-06-04
SK66099A3 (en) 2000-01-18
NO992399D0 (no) 1999-05-19
KR20000053343A (ko) 2000-08-25
ATE223217T1 (de) 2002-09-15
NZ334949A (en) 2000-12-22
CZ174899A3 (cs) 1999-08-11
TNSN97184A1 (fr) 2005-03-15
IL129607A0 (en) 2000-02-29
OA11047A (fr) 2003-03-07
DE69715247D1 (de) 2002-10-10
ZA9710435B (en) 1998-06-10
CA2271095C (fr) 2004-08-03
TR199901096T2 (xx) 1999-07-21
AU5125698A (en) 1998-06-10
EP0949923A1 (fr) 1999-10-20

Similar Documents

Publication Publication Date Title
GR930300060T1 (en) Enhanced blended and portland cement compositions.
IL123648A0 (en) 1,4-Benzothiazepine-1,1-dioxides their preparation and pharmaceutical compositions containing them
EP0538989A3 (en) Well cement compositions and their use
LT97200A (en) Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof
ZA907720B (en) Enhanced blended and portland cement compositions
DK0728148T3 (da) Forbedrede immunogene sammensætninger mod humant gastrin 17
UA32523C2 (uk) Пептиди, які мають високу біологічну активність, та фармацевтична композиція на їх основі
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
YU22499A (sh) Stabilizovane farmaceutske smeše na bazi hinupristina i dalfopristina i njihovo dobijanje
HRP20030002A2 (en) STABLE GABAPENTIN HAVING pH WITHIN A CONTROLLED RANGE
IL135723A (en) 1'-Ä4-Ä1-4-Fluorophenyl)-1H-indole-3-ylÜ-1-butylÜ-spiroÄisobenzofuran-1-(3H),4'-piperidineÜhydrohal ogenides and pharmaceutical compositions containing them
IL109275A0 (en) 5-acylamino-1,2,4-thiadiazoles, their preparation and pharmaceutical compositions containing them
HUP0102025A3 (en) Derivatives of 1,3,4-oxadiazolone, pharmaceutical compositions containing them and their use
IL110809A0 (en) 1,5-diphenyl-3-pyrazolylalkyl-n-hydroxydithiocarbamates and pharmaceutical compositions containing them
IL108624A0 (en) Pseudopeptides, their preparation and pharmaceutical compositions containing them
BG103306A (en) Liquid allendronate compositions
NZ337798A (en) Pharmaceutical compositions containing lamivudine
MD970269A (en) Clavulanates
SI0835656T1 (en) Combination drug containing tramadol and a calcium channel antagonist
MD1714F2 (en) Therapeutical composition in the form of syrup, containing N-acetylcysteine
IL77426A (en) 2,6-dimethyl-8alpha-pivaloyl-amino-9,10-didehydro-ergoline,its production and pharmaceutical compositions containing it
NO943373D0 (no) Psyliumholdig sammensatt blandingsdrikk
NZ326769A (en) High-content famciclovir tablets
LT97045A (en) Composition of aperitive ingredients
MX9702290A (es) Preparado medicamentoso solido que contiene (4-trifluorometil)-anilida de acido 5-metil-isoxazol-4-carboxilico.